Bausch + Lomb: Character Biosciences: $93 Million (Series B) Secured For Advancing Precision Medicine For Progressive Eye Diseases

Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases, starting with age-related macular degeneration (AMD). This funding round was co-led by new investors aMoon and Luma Group, with additional participation from Bausch + Lomb and Jefferson Life Sciences, alongside existing investors Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures. The post Character Biosciences: $93 Million (Series B) Secured For Advancing Precision Medicine For Progressive Eye Diseases appeared first on Pulse 2.0.